NOVARTIS

Clinical Trial Results Summary

A clinical trial to learn more about the safety of brolucizumab in people with neovascular age-related macular degeneration (nAMD)

Thank you!

Thank you to the participants who took part in the clinical trial for **nAMD**. Every participant helped the researchers learn more about the trial drug **RTH258**, also called **brolucizumab**.

Novartis sponsored this trial and believes it is important to share what was learned from the results of this trial with the participants and the public. We hope this helps the participants understand their important role in medical research.

Trial information

Trial number: CRTH258AIN01

Drug studied: RTH258, also known as **brolucizumab**

Sponsor: Novartis

If you were a participant and have any questions about the results, please talk to the doctor or staff at the trial site.

This summary only shows the results of a single clinical trial. Other clinical trials may have different findings.

What was the main purpose of this trial?

The purpose of this trial was to learn more about the safety of **brolucizumab** in people with **neovascular age-related macular degeneration** (**nAMD**). To find this out, researchers included participants from India, aged 50 years or older.
These participants closely resemble the real-world population intended to be treated with **brolucizumab**.

What is real-world population?

Real-world population are patients treated in routine healthcare practice.

nAMD is an eye disease that develops in some people as they grow older. In this disease, the back of the eye, also called the retina, can form new abnormal vessels that carry blood and fluid.

These newly formed vessels are very weak and can leak blood and fluid. This can cause a blind spot or distortion in the central vision.

Central vision is needed for seeing objects clearly and for common daily tasks such as reading and driving.



Brolucizumab is a medicine approved for the treatment of **nAMD** in the USA, Europe, and India. In this trial, researchers wanted to know how well **brolucizumab** works in people with **nAMD**.

Trial drug
Brolucizumab
Pronounced as
BROE-lue-SIZ-ue-mab

The trial's purpose was to answer these main questions:

- What ocular and non-ocular adverse events did the participants have that were suspected to be related to **brolucizumab** until Week 56?
- What adverse events did the participants have during this trial?
  - ↳ An **adverse event** is any sign or symptom that participants have during a trial.

How long was this trial?

The trial began in March 2022 and ended in August 2023. It was planned for each participant to be in the trial for about 13 months after the start of the trial treatment.

Who was in this trial?

105 participants from India with **nAMD** received treatment in this trial. Participants' ages ranged from 50 to 91 years. Their average age was 68 years. The number of participants by gender is shown below.

Gender

63 Men	42 Women

Trial doctors could include participants who were:

- aged 50 years or older, with **nAMD**, and
- never treated for their **nAMD**.

In cases where both eyes were affected, only one eye was selected as the study eye and treated with **brolucizumab**, based on the officially approved conditions on how to use it.

What treatments did the participants receive?

All participants received:

Brolucizumab, 6 milligrams (mg) given as an injection into the eye every 4 weeks for the first 3 doses, and then either every 12 weeks or 8 weeks, based on the doctor's decision.

What happened during this trial?

Before treatment — On Day 1

Trial doctors checked if participants could take part in this trial.

During treatment — About 11 Months

A total of 105 participants received treatment. The study had in 2 parts:

- **Part 1:** **Brolucizumab 6 mg** was given every 4 weeks from Day 1 to Week 8 as an injection directly into the eye.
  At Week 16, participants' eyes were tested to find out the effects of **brolucizumab**.
- **Part 2:** From Week 16 onward, **brolucizumab 6 mg** was given either once every 12 weeks or every 8 weeks until Week 48, based on the trial doctor's assessment of the disease.

After treatment — About 2 Months

Trial doctors checked participants about 2 months after their last treatment.

What was the main result of this trial?

In this trial, researchers wanted to distinguish between adverse events that happened in the eye (ocular adverse events) and in other parts of the body (non-ocular adverse events).

What ocular and non-ocular adverse events did the participants have that were suspected to be related to brolucizumab until Week 56?

- 3% of participants (3 out of 105) had 4 adverse events during 56 weeks of treatment. Of which, 2 participants left the trial due to adverse events.
- All adverse events happened in the eye while on treatment.

Number of Participants (%) With Ocular Adverse Events That Were Suspected to Be Related to Brolucizumab

	Brolucizumab 6 mg 105 participants
Blockage of the blood vessels due to inflammation in the eye Retinal vasculitis	1 of 105 1%
Inflammation of gel like part (vitreous cavity) of the eye Vitritis	2 of 105 2%
Inflammation in the walls of the eye Uveitis	1 of 105 1%

There were no non-ocular **adverse events** that were suspected to be related to **brolucizumab**.

What were the other results of this trial?

What was the change in vision test score from Day 1 to Week 56?

Vision test score improved by about 15 ETDRS letters at Week 56 compared to Day 1.

What is ETDRS chart

It is a test chart that has rows of letters from large to small size. It is used to test the vision in patients.

How many participants had their brolucizumab injections once every 12 weeks?

70% of participants (74 out of 105) had their **brolucizumab** injections once every 12 weeks.

How many participants did not have fluid in the retina at Week 56?

41% of participants (43 out of 105) did not have fluid inside the retina and 29% of participants (30 out of 105) did not have fluid underneath the retina at Week 56, following treatment with **brolucizumab**.

Did the treatment with brolucizumab reduce the thickness of the central part of the retina at Week 56?

Yes, treatment with **brolucizumab** reduced the thickness of the central part of the retina from 335 micrometers (µm) at the beginning of the study to 230 µm at Week 56.

What adverse events did the participants have?

Trial doctors keep track of all **adverse events** that happen in trials, even if they think the adverse events are not related to the trial treatments.

Many trials are needed to know if a drug or treatment causes an adverse event.

This section is a summary of the adverse events that happened from the start of treatment to about 2 months after the last treatment.

An **adverse event** is:

- Any **sign or symptom** that the participants have during a trial
- Considered **serious** when it is life-threatening, causes lasting problems, the participant needs hospital care, or results in death

Adverse events **may** or **may not** be caused by treatments in the trial.

64% of participants (67 of 105) had adverse events. None of the participants had adverse events that were considered serious.

No participants died. 4 participants left the trial due to an adverse event.

The researchers concluded there were no new safety concerns for **brolucizumab** in this trial.

How many participants had adverse events?

The number of participants with ocular or non-ocular adverse events is presented in the table below.

Number of Participants (%) With Ocular Adverse Events

Participants who:	Brolucizumab 6 mg 105 participants
Had at least 1 adverse event in the treated eye	45 of 105 43%
Left the trial due to an adverse event	4 of 105 4%

Number of Participants (%) With Non-Ocular Adverse Events

Participants who:	Brolucizumab 6 mg 105 participants
Had at least 1 adverse event in the body, apart from the treated eye	31 of 105 30%

What serious adverse events did the participants have?

None of the participants had serious adverse events. No participant died.

What other adverse events did the participants have?

67 participants had other adverse events.

The table below shows the other adverse events that happened in **5 or more** participants.

Number of Participants (%) With Most Common Ocular Other Adverse Events

	Brolucizumab 6 mg 105 participants
Blood spots on white part of the treated eye Conjunctival hemorrhage- Study Eye	**13 of 105** 12%
Blurry vision of the treated eye Vision blurred- Study Eye	**6 of 105** 6%
Clouding of the lens of the treated eye Cataract- Study Eye	**8 of 105** 8%
Redness in the treated eye Ocular hyperemia- Study Eye	**7 of 105** 7%

Number of Participants (%) With Most Common Non-Ocular Other Adverse Events

	Brolucizumab 6 mg 105 participants
Fever Pyrexia	**13 of 105** 12%
Headache	**8 of 105** 8%

What was learned from this trial?

Researchers learned about the safety of **brolucizumab** in people with **nAMD** from India.

- Researchers found no new safety concerns with **brolucizumab**.
- Researchers found **brolucizumab** 6 mg to be safe and effective in real-world **nAMD** patients.

At the time this report was created, there were plans for future trials with **brolucizumab** in people with **nAMD**.

Where can I learn more about this trial?

More information about the results and adverse events in this trial can be found in the scientific summary of the results available on the Novartis Clinical Trial Results website **www.novctrd.com**

Follow these steps to find the scientific summary:



For more information about this trial, go to the website:

- **clinicaltrials.gov** – search using the number **NCT05269966**

  or local regional registries by searching with the trial code.

Other trials will appear on the public websites above. When there, search for **RTH258** and /or **brolucizumab**.

Full clinical trial title: A real-world, prospective, multi-center, open-label, phase IV clinical study to evaluate the safety and effectiveness of intravitreal injections (IVI) of brolucizumab in patients with neovascular age-related macular degeneration (nAMD)

Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients worldwide.

1-888-669-6682 (US) | +41-61-324 1111 (EU)

www.novartis.com/clinicaltrials